



HAL
open science

Characterization of Extended-Spectrum Beta-Lactamase–Producing *Salmonella enterica* Serotype Brunei and Heidelberg at the Hussein Dey Hospital in Algiers (Algeria)

Rachida Kermas, Abdelaziz Touati, Lucien Brasme, Elisabeth Le
Magrex-Debar, Sadjia Mehrane, François-Xavier Weill, Christophe de Champs

► **To cite this version:**

Rachida Kermas, Abdelaziz Touati, Lucien Brasme, Elisabeth Le Magrex-Debar, Sadjia Mehrane, et al.. Characterization of Extended-Spectrum Beta-Lactamase–Producing *Salmonella enterica* Serotype Brunei and Heidelberg at the Hussein Dey Hospital in Algiers (Algeria). 2012. pasteur-01115981

HAL Id: pasteur-01115981

<https://pasteur.hal.science/pasteur-01115981>

Preprint submitted on 12 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1 **Nosocomial outbreaks of extended-spectrum beta-lactamase-producing**
2 ***Salmonella enterica* serotype Brunei and Heidelberg at the Hussein Dey**
3 **hospital in Algiers (Algeria)**

4 Rachida KERMA¹, **Abdelaziz TOUATI**¹, Lucien BRASME³, Elisabeth LE MAGREX-
5 DEBAR³, Sadjia MEHRANE², François-Xavier WEILL⁴, and Christophe DE
6 CHAMPS³

7 ¹ Département de microbiologie, FSNV, Université A/MIRA de Bejaia 06000, Algeria

8 ² Laboratoire central de biologie clinique, CHU HUSSEIN DEY, Alger, Algeria

9 ³ Laboratoire de Bactériologie–Virologie-Hygiène Hospitalière, CHU Reims, Hôpital
10 Robert DEBRE, Avenue du Général Koenig, 51092 Reims Cedex, France

11 ⁴ Institut Pasteur, Centre national de référence des Salmonella, Unité des Bactéries
12 Pathogènes Entériques, 28 rue du docteur Roux, Paris cedex 15, France.

13 **Corresponding author's**

14 Abdelaziz TOUATI

15 Département de microbiologie, FSNV, Université A/MIRA de Béjaia, 06000, Algeria

16 Mail: ziz1999@yahoo.fr

17 Tel/fax : 213.34214762

18 **Abstract**

19 **Objectives:** The purpose of this work was to study the genetic determinants
20 responsible for extended-spectrum β -lactamase (ESBL) resistance of *Salmonella*
21 isolated from children during the period 1995 to 2008 at the Hussein Dey hospital in
22 Algiers (Algeria).

23 **Methods:** Fourteen ESBL-resistant *Salmonella* isolates were tested towards 22
24 antimicrobial agents. PCR and sequencing were used to determine the underlying
25 genetic determinants responsible for the ESBL phenotypes. The transferability of the
26 ESBL phenotypes was tested by conjugation, and ERIC-PCR was employed to
27 typing the isolates.

28 **Results:** All isolates were resistant to ticarcillin, ticarcillin-clavulanate, piperacillin,
29 amoxicillin-clavulanate, cefuroxime, aztreonam, ceftazidime, cefotaxime (except 2
30 isolates), cefepime and cefpirome. PCR and DNA sequencing identified these
31 extended-spectrum β -lactamases as TEM-48 (n=6), TEM-4 (n=3), CTX-M-15 (n=4),
32 and one new TEM, designated TEM-188.

33 **Conclusion:** this study demonstrates the emergence of a public health risk related
34 to ESBL in *Salmonella* in Algeria.

35 **Keywords:**

36 Outbreaks, Children, *Salmonella* Brunei, Heidelberg, Extended-spectrum β -
37 lactamase, TEM-188

38 INTRODUCTION

39 Non-typhoidal salmonellae are one of the principal pathogens implicated in food-
40 borne gastroenteritis worldwide. Animals and their products, particularly meat,
41 chicken eggs, and milk, are major sources of human infection. The incidence of non-
42 typhoidal *Salmonella* infections has increased considerably in many countries, but
43 with marked differences among countries (Makanera *et al.*, 2003). Although
44 antibiotics are not usually recommended in cases of *Salmonella* Enterocolitis, they
45 are crucial in systemic infections. Extra-intestinal infectious complications, including
46 meningitis, sepsis and bacteraemia are more common in infants and the elderly, and
47 in immunocompromised patients. In these potentially life-threatening cases, the
48 antibiotics of choice are fluoroquinolones and extended-spectrum cephalosporins.
49 *Salmonella spp.* resistant to extended-spectrum cephalosporins have been
50 recognized since 1988, and are increasing in prevalence worldwide. This is of
51 particular concern for the treatment of salmonellosis in children, because
52 fluoroquinolones should not be used in this age group (Kruger *et al.*, 2004 ; Yates
53 and Amyes, 2005).

54 To date, more than 340 β -lactamases have been described. *Salmonella* have been
55 found to express a wide variety of ESBL types, including TEM (Ait Mhand *et al.*,
56 2002), SHV (Hammami *et al.*, 1991), PER (Casin *et al.*, 2003), OXA (Hanson *et al.*,
57 2002), and CTX-M (Tamang *et al.*, 2011), and, more recently, plasmid-mediated
58 AmpC type enzymes, such as DHA-1 (Barnaud *et al.*, 1998), CMY-2 (Koeck *et al.*,
59 1997), and ACC-1 (Rhim-Mahjoubi *et al.*, 2002).

60 In Algeria, ESBLs have been identified in nosocomial isolates of various
61 *Enterobacteriaceae*, such as *E. coli*, *K. pneumoniae* and *E. cloacae* (Touati *et al.*,
62 2006; Ibadene *et al.*, 2008; Messai *et al.*, 2008, Ramdani-Bouguessa *et al.*, 2011).
63 However, only few reports for the presence of these enzymes in *Salmonella* have
64 been published (Naas *et al.*, 2005; Touati *et al.*, 2008; Ibadene *et al.*, 2009; Naas *et*
65 *al.*, 2011; Bouzidi *et al.*, 2011).

66 In this study, we characterized the ESBLs in a collection of putative ESBL positive
67 *Salmonella* spp. isolated from 1995 to 2008 at the Hussein Dey hospital in Algiers
68 (Algeria).

69 **METHODS**

70 **Bacterial isolates**

71 A collection of 14 non-duplicate amoxicillin-resistant *S. enterica* isolates was
72 examined. They were obtained from stool samples of children between 1995 and
73 2008 at the Hussein Dey hospital in Algiers (Algeria). All isolates were biochemically
74 identified by using the API 20E identification system (BioMérieux, Marcy l'Étoile,
75 France).

76 All isolates were serotyped at the French National Reference Center for Salmonella,
77 Institut Pasteur, Paris, France on the basis of somatic O, phase 1 flagellar, and
78 phase 2 flagellar antigens by agglutination tests with antisera (BioRad, Marnes-la-
79 coquette, France). The serotypes were designated according to the White-
80 Kauffman-Le Minor scheme.

81 **Susceptibility testing and ESBL detection**

82 Disk diffusion susceptibility tests for aztreonam, ticarcillin, piperacillin, amoxicillin-
83 clavulanate, ticarcillin-clavulanate, cefoxitin, cefpirome, cefepime, piperacillin-
84 tazobactam, cefuroxime, imipenem, tobramycin, amikacin, gentamicin, kanamycin,
85 sulfonamide, trimethoprim-sulfamethoxazole, nalidixic acid, ciprofloxacin,
86 tetracycline and chloramphenicol (BioRad) were performed according to the
87 recommendations of the Antibiogram Committee of the French Society for
88 Microbiology (<http://www.sfm.asso.fr/>). Minimum inhibitory concentrations (MICs) for
89 amoxicillin, cefotaxime, ceftazidime and ceftriaxone were determined by Etest (AB
90 BIODISK, Solna, Sweden) performed on Mueller–Hinton agar plates as
91 recommended by the manufacturer.

92 Extended-Spectrum β -Lactamase (ESBL) production was detected by a double-disk
93 synergy test (DDST) and was performed by placing disks of ceftazidime, cefotaxime

94 and aztreonam at a distance of 20mm (centre to centre) from a disk with
95 amoxicillin/clavulanic acid (20/10 µg). Enhancement of the inhibition zone between
96 the disks containing clavulanic acid and cefotaxime, ceftazidime or aztreonam
97 indicated the ESBL production (Jarlier *et al.*, 1988).

98 **β-Lactamases characterization**

99 Total DNA was extracted by using the QIAmp DNA mini kit (Qiagen, Courtaboeuf,
100 France) according to the instructions of the manufacturer. The ESBL-encoding
101 genes *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M} were detected by PCR using specific primers
102 (Table 1) and further identified by nucleotide sequence analysis of the PCR
103 products. Sequences were analyzed using the BLAST 2.0 (Basic Local Alignment
104 Search Tool) software available on the website of the National Center for
105 Biotechnology Information (<http://www.ncbi.nlm.nih.gov/blast/BLAST.cgi>)

106 **PCR fingerprinting**

107 For enterobacterial repetitive intergenic consensus (ERIC) PCR, whole-cell DNA of
108 isolates was extracted using the QIAmp DNA mini kit (Qiagen). The primers were
109 ERIC1 (5'-ATGTAAGCTCCTGGGGATTAC-3') and ERIC2 (5'-
110 AAGTAAGTACTGGGGTGAGCG-3'). Each 23 µl PCR reaction mixture contained 25
111 pmol of each primer, 5mmol/L each deoxynucleotide triphosphate (dNTP) and 2.5 U
112 of Taq polymerase (Qiagen, Courtaboeuf, France) in the manufacturer's provided
113 buffer. Two microliters of total DNA (about 80 ng) was added to each reaction to
114 reach the final 25µl PCR reaction volume. The ERIC-PCR parameters were as
115 follows: initial denaturation at 95°C for 7 min; 30 cycles of denaturation at 92°C for
116 30 s, annealing at 50°C for 1 min, and extension at 65°C for 8 min; followed by a
117 final extension at 65°C for 16 min (Cao *et al.*, 2008). PCR amplicons were resolved

118 on 1% agarose gel containing ethidium bromide by horizontal electrophoresis in Tris-
119 borate-EDTA buffer. Gels were visualized under UV light with Bio-Profil (Vilbert
120 Lourmat, Torcy, France).

121 **RESULTS**

122 Fourteen strains belonging to *Salmonella enterica* serotypes Brunei (10 strains) and
123 Heidelberg (4 strains) were isolated and serotyped in the laboratory and confirmed at
124 the Pasteur Institute in Paris, France. Te strains were isolated from infants.

125 All isolates exhibited resistance or decreased susceptibilities to ticarcillin, ticarcillin-
126 clavulanate, piperacillin, amoxicillin-clavulanate, cefuroxime, aztreonam, ceftazidime,
127 cefotaxime, cefepime and cefpirome (table 2). They remained susceptible to
128 imipenem, cefoxitin and piperacillin-tazobactam. The DDS test was positive for all of
129 these isolates. MICs determination showed that *S. Brunei* examined (Table 3) were
130 resistant to amoxicillin (MIC > 256µg/ml), ceftazidime (MIC = 64µg/ml), cefotaxime
131 (MIC = 16µg/ml) and ceftriaxone (MIC = 6µg/ml). For *S. Heidelberg* strains,
132 resistance were observed for all strains (amoxicillin: MIC > 256µg/ml, ceftazidime:
133 MIC = 48µg/ml, cefotaxime: MIC > 32µg/ml and ceftriaxone: MIC > 32µg/ml)

134 All isolates were resistant to gentamicin and tobramycin. The isolates of *S. Brunei*
135 were resistant to kanamycin and amikacin (except isolates of S9 and S12).
136 Resistance to nalidixic acid was observed in all isolates of *S. Heidelberg*. All of the
137 strains were susceptible to ciprofloxacin, cotrimoxazole, tetracycline and
138 chloramphenicol.

139 TEM consensus PCR assays gave the expected PCR fragments for the 10 strains of
140 *S. Brunei* (Table 2) and CTX-M amplifications were positive for the 4 strains of *S.*
141 *Heidelberg*. SHV amplification was negative.

142 Three isolates of *S. Brunei* (S9, S12 and S22) harbored the *bla*_{TEM-4} gene and the
143 *bla*_{TEM-48} gene was found in six isolates of *S. Brunei* (S15, S16, S18, S20, S21 and
144 S23). The four strains of *S. Heidelberg* were found to produce CTX-M-15.

145 One strain of *S. Brunei* (S10) was found to produce a new TEM. This protein has
146 been designated TEM-188 (<http://www.lahey.org/studies/webt.htm>, GenBank
147 Accession Number JN211012). The new TEM β -lactamase differed from TEM-1 by
148 three substitutions: Leu21Phe, Gly238Ser and Glu240Lys. These substitutions are
149 identical to those found in TEM-48. However, TEM-48 has an additional substitution,
150 Thr265Met. Isolates producing TEM-48 and TEM-188 showed identical antibiotypes
151 (table 2 and 3) suggesting that the substitution Thr265Met in TEM-48 has no effect
152 on β -lactams susceptibility.

153 The ERIC-PCR method was applied to the six TEM-48-producing *S. Brunei* strains
154 and the four CTX-M-15-producing-*S. Heidelberg*. Two ERIC-PCR patterns were
155 observed, one for the six *S. Brunei* and a second one for the four *S. Heidelberg*,
156 suggesting a clonal expansion for each resistant population defined by its serotype.

157 **Discussion**

158 There are a number of commonly identified serotypes of *Salmonella* associated with
159 human infections. In the United States, the most common serovars were
160 Typhimurium, Enteritidis, Newport, Heidelberg, and Javiana. In other parts of the
161 world, there are some differences in the predominant serovars associated with
162 disease. In the European Union, Enteritidis is the predominant serovar. In many
163 parts of Asia, Choleraesuis is one of the top serovars (Foley and Lynne, 2007). *S.*
164 Brunei has been rarely reported from animals, animal food products, and patients
165 with human salmonellosis. There are only 3 articles found on pubmed when we use
166 *Salmonella* Brunei as keyword.

167 In our study, 10 strains of *S.* Brunei were recovered from infants during the period
168 1995 to 2008 whereas the 4 *S.* Heidelberg were recovered only in October 2008.
169 Unfortunately, data of the commonly identified serotypes in Algeria were not
170 available.

171 The largest subset of the population for which antibiotic susceptibility of *Salmonella*
172 is a major concern is children. Although, gastroenteritis is the most frequent clinical
173 manifestation, systemic infections are common, and even cases of meningitis have
174 been reported. Such serious infections are most common in children and the elderly.
175 Antibiotic therapy is strongly recommended in such cases (Arlet *et al.*, 2006).
176 Extended-spectrum cephalosporins are commonly used to treat patient with invasive
177 infections or severe diarrhea caused by *Salmonellae*; however, during the past years
178 extended-spectrum cephalosporins-resistant *Salmonellae* have frequently been
179 reported worldwide, including north Africa (Ahmed *et al.*, 2009; Ohmani *et al.*, 2010;
180 Bouzenoune *et al.*, 2011; Naas *et al.*, 2011).

181 The 1st salmonella strains with ESBLs in Africa were identified in 1988 in Tunisia
182 (Hammami *et al.*, 1991). TEM-4 β -lactamase, which differed from the TEM-1 β -
183 lactamase sequence by 4 substitutions (Leu21Phe, Glu104Lys, Gly238Ser and
184 Thr265Met), was first reported for *E. coli* in France by Paul *et al.* (Paul *et al.*, 1989)
185 This enzyme was described in an isolate of *Salmonella* collected during a French
186 national survey in 1998 (De Champs *et al.*, 2000) and reported in isolates of
187 *Salmonella* serotype Mbandaka in Tunisia (Makanera *et al.*, 2003). This was the first
188 reported identification of the TEM-4 ESBL in Algerian *Salmonella* Brunei.

189 The amino acid substitutions of the sequence of TEM-48 compared to the TEM-1 β -
190 lactamase sequence were Leu21Phe, Gly238Ser, Glu240Lys and Thr265Met. TEM-
191 48 was first described in *K. pneumoniae* strains in Poland in Poland (Gniadkowski *et*
192 *al.*, 1998). To our knowledge, no report on TEM-48 isolated from *Salmonella* has
193 been previously published. Moreover, all isolates of *S. Brunei* producing TEM-48
194 were resistant to aminoglycosides and sulfonamide.

195 CTX-M-15 was identified in different salmonella serotypes, but to our knowledge, this
196 is the first report of CTX-M-15 in *S. Heidelberg* isolates. CTX-M-15-producing
197 *Salmonella* isolates were reported in different serotypes in Algeria, including Infantis
198 (Naas *et al.*, 2011) and Kedougou (Touati *et al.*, 2008). The four isolates of *S.*
199 Heidelberg were found resistant to nalidixic acid, but susceptible to fluoroquinolones.
200 PCR for the plasmid-mediated mechanisms were negative for the four isolates,
201 suggesting that the nalidixic resistance was probably mediated by mutations in
202 topoisomerases.

203 PCR-mediated genome fingerprinting based on ERIC or REP has been found useful
204 for the typing of outbreak and sporadic *Salmonella* isolates (Merino *et al.*, 2003).

205 Nosocomial outbreaks due to ESBLs-producing *Salmonella* have been described in
206 many countries, such as the outbreak in Tunisia due to TEM-4-producing *S.*
207 Mbandaka (Makanera et al., 2003). The great majority of them have involved
208 pediatric wards and especially neonatology units. In the community, many outbreaks
209 have been reported and were largely foodborne outbreaks (Arlet et al., 2006). The
210 two clonal strains observed in our study, were recovered throughout the 13-year
211 study period. The *S.* Brunei-producing TEM-48 strains were recovered from
212 neonatology ward, except one strain recovered from cradle ward, whereas the *S.*
213 Heidelberg-producing CTX-M-15 strains were isolated in cradle ward in which the
214 age of children is about 3 months. These observations indicated that gastrointestinal
215 infections were caused mainly by clonally related *Salmonella* serotype isolates and
216 clonal spread was responsible for their dissemination.

217 Salmonellosis is most often attributed to the consumption of contaminated foods
218 such as poultry, beef, pork, eggs, milk, seafood, nut products, and fresh produce
219 (Foley and Lynne, 2007). In this outbreak, food as a source was excluded because
220 milk was commercially prepared and other infants, hospitalized in the same ward at
221 the same period, were fed with the same preparations but did not become infected
222 with these strains. Therefore, a horizontal transmission of the outbreak strain had
223 probably occurred.

224 In conclusion, this study demonstrates the emergence of a public health risk related
225 to β -lactams resistance in *Salmonella* in Algeria. The implementation of effective
226 screening methods for the detection of beta-lactamases and ESBLs as well as the
227 establishment of surveillance programs became key factors in the control of hospital
228 outbreaks.

229 **Acknowledgments**

230 We thank Janick Madoux for her technical assistance.³

231 **References**

232 **Ahmed, A.M, Younis, E.E., Ishida, Y. & Shimamoto, T.** (2009). Genetic basis of
233 multidrug resistance in *Salmonella enterica* serovars Enteritidis and Typhimurium
234 isolated from diarrheic calves in Egypt. *Acta Trop* **111**:144-9

235 **Ait Mhand, R., Soukri, A., Moustouli, N., Amarouch, H., El Mdaghri, N., Sirot, D.**
236 **& Benbachir, M.** (2002). Plasmid-mediated TEM-3 extended-spectrum beta-
237 lactamase production in *Salmonella typhimurium* in Casablanca. *J.Antimicrob.*
238 *Chemother* **49**:169–172.

239 **Arlet G,** Barrett TJ, Butaye P, Cloeckeaert A, Mulvey MR, White DG. **Salmonella** resistant to
240 extended-spectrum cephalosporins: prevalence and epidemiology. *Microbes Infect.* 2006
241 Jun;8(7):1945-54

242 **Barnaud, G., Arlet, G., Verdet, C., Gaillot, O., Lagrange, P.H. & Philippon A.**
243 (1998). *Salmonella enteritidis* AmpC plasmid-mediated inducible beta-lactamase
244 (DHA-1) with an ampR gene from *Morganella morganii*. *Antimicrob Agents*
245 *Chemother* **42**:2352-8.

246 **Bouzidi, N., Aoun, L., Dekhil, M., Granier, S.A., Poirel, L., Brisabois, A.,**
247 **Nordmann, P. & Millemann, Y.** (2011). Co-occurrence of aminoglycoside resistance
248 gene *armA* in non-Typhi *Salmonella* isolates producing CTX-M-15 in Algeria. *J*
249 *Antimicrob Chemother* **66**:2180-1.

250 **Bouzenoune, F., Kellab Debbih, K., Boudersa, F., Kouhil, S. & Nezzar, N.** (2011).
251 Antibiotic susceptibility of *Salmonella enterica* serovar Typhi isolated from blood
252 cultures at the Ain M'lila hospital (Algeria), between 2005 and 2008. *Med Mal Infect*
253 **41**:181-5.

254 **Brasme, L., Nordmann, P., Fidel, F., Lartigue, M.F., Bajolet, O., Poirel, L., Forte,**
255 **D., Vernet-Garnier, V., Madoux, J. & other authors.** (2007). Incidence of class A
256 extended-spectrum beta-lactamases in Champagne-Ardenne (France): a 1 year
257 prospective study. *J Antimicrob Chemother* **60**:956-64.

258 **Cao, S.Y., Wang, M.S., Cheng, A.C., Qi, X.F., Yang, X.Y., Deng, S.X., Yin, N.C.,**
259 **Zhang, Z.H., Zhou, D.C. & other authors.** (2008). Comparative analysis of
260 intestinal microbial community diversity between healthy and orally infected
261 ducklings with *Salmonella enteritidis* by ERIC-PCR. *World J Gastroenterol* **14**:1120-
262 5.

263 **Casin, I., Hanau-Berçot, B., Podglajen, I., Vahaboglu, H. & Collatz, E.** (2003).
264 *Salmonella enterica* serovar Typhimurium bla(PER-1)-carrying plasmid pST11 encodes an
265 extended-spectrum aminoglycoside 6'-N-acetyltransferase of type Ib. *Antimicrob. Agents*
266 *Chemother* **47**:697–703.

267 **Chanal, C., Bonnet, R., De Champs, C., Sirot, D., Labia, R. & Sirot, J.** (2000)
268 Prevalence of beta-lactamases among 1,072 clinical strains of *Proteus mirabilis*: a 2-
269 year survey in a French hospital. *Antimicrob Agents Chemother* **44**:1930-5.

270 **De Champs, C., Sirot, D., Chanal, C., Bonnet, R. & Sirot J.** (2000). A 1998
271 survey of extended-spectrum beta-lactamases in *Enterobacteriaceae* in France. The
272 French Study Group. *Antimicrob Agents Chemother* **44**:3177-9.

273 **Dutour, C., Bonnet, R., Marchandin, H., Boyer, M., Chanal, C., Sirot, D. & Sirot**
274 **J.** (2002). CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from
275 *Enterobacteriaceae* isolated in France. *Antimicrob Agents Chemother* **46**:534-7.

276 **Foley SL, Lynne AM, Nayak R.** Salmonella challenges: prevalence in swine and poultry and
277 potential pathogenicity of such isolates. J Anim Sci. 2008 Apr;86(14 Suppl):E149-62

278 **Gniadkowski, M., Schneider, I., Jungwirth, R., Hryniewicz, W. & Bauernfeind, A.**
279 (1998). Ceftazidime-resistant *Enterobacteriaceae* isolates from three Polish
280 hospitals: identification of three novel TEM- and SHV-5-type extended-spectrum
281 beta-lactamases. Antimicrob Agents Chemother **42**:514-20.

282 **Hammami, A., Arlet, G., Ben Redjeb, S., Grimont, F., Ben Hassen, A., Rekik, A.**
283 **& Philippon A.** (1991). Nosocomial outbreak of acute gastroenteritis in a neonatal
284 intensive care unit in Tunisia caused by multiply drug resistant *Salmonella* wien
285 producing SHV-2 beta-lactamase. Eur J Clin Microbiol Infect Dis **10**:641-6.

286 **Hanson, N.D., Moland, E.S., Hossain, A., Neville, S.A., Gosbell, I.B. &**
287 **Thomson, K.S.** (2002). Unusual *Salmonella enterica* serotype Typhimurium isolate
288 producing CMY-7, SHV-9 and OXA-30 beta-lactamases. J. Antimicrob. Chemother
289 **49**:1011–1014.

290 **labadene, H., Messai, Y., Ammari, H., Ramdani-Bouguessa, N., Lounes, S.,**
291 **Bakour, R. & Arlet, G.** (2008). Dissemination of ESBL and Qnr determinants in
292 *Enterobacter cloacae* in Algeria. J Antimicrob Chemother **62**:133-6

293 **labadene, H., Bakour, R., Messai, Y., Da Costa, A. & Arlet, G.** (2009). Detection of
294 blaCTX-M-14 and aac(3)-II genes in *Salmonella enterica* serotype Kedougou in
295 Algeria. Med Mal Infect **39**:806-7

296 **Jarlier, V., Nicolas, M.H., Fournier, G. & Philippon, A.** (1988). Extended-spectrum
297 β -lactamases conferring transferable resistance to newer β -lactam agents in
298 *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. Rev Infect Dis
299 **10**:867–78.

300 **Koeck, J.L., Arlet, G., Philippon, A., Basmaciogullari, S., Thien, H.V., Buisson.,**
301 **Y. & Cavallo, J.D.** (1997). A plasmid-mediated CMY-2 beta-lactamase from an
302 Algerian clinical isolate of *Salmonella senftenberg*. FEMS Microbiol Lett Jul **15**:255-
303 60.

304 **Kruger, T., Szabo, D., Keddy, K.H., Deeley, K., Marsh, J.W., Hujer, A.M.,**
305 **Bonomo, R.A. & Paterson, DL.** (2004). Infections with nontyphoidal *Salmonella*
306 species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa.
307 Antimicrob Agents Chemother **48**:4263-70

308 **Kojima, A., Ishii, Y., Ishihara, K., Esaki, H., Asai, T., Oda, C., Tamura, Y.,**
309 **Takahashi, T. & Yamaguchi, K.** (2005). Extended-spectrum-beta-lactamase-
310 producing *Escherichia coli* strains isolated from farm animals from 1999 to 2002:
311 report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program.
312 Antimicrob Agents Chemother **49**:3533-7.

313 **Makanera, A., Arlet, G., Gautier, V. & Manai, M.** (2003). Molecular epidemiology
314 and characterization of plasmid-encoded beta-lactamases produced by Tunisian
315 clinical isolates of *Salmonella enterica* serotype Mbandaka resistant to broad-
316 spectrum cephalosporins. J Clin Microbiol **7**, 2940-5.

317 **Merino, L.A., Ronconi, M.C., Navia, M.M., Ruiz, J., Sierra, J.M., Cech, N.B.,**
318 **Lodeiro, N.S. & Vila, J.** (2003) Analysis of the clonal relationship among clinical
319 isolates of *Salmonella enterica* serotype Infantis by different typing methods. Rev
320 Inst Med Trop Sao Paulo **45** :119-23.

321 **Messai, Y., Ibadene, H., Benhassine, T., Alouache, S., Tazir, M., Gautier, V.,**
322 **Arlet, G. & Bakour, R.** 2008. Prevalence and characterization of extended-spectrum

323 beta-lactamases in *Klebsiella pneumoniae* in Algiers hospitals (Algeria). Pathol Biol
324 (Paris) **56**:319-25

325 **Naas, T., Lezzar, A., Bentchouala, C., Smati, F., Scheftel, J.M., Monteil, H. &**
326 **Nordmann, P.** (2005). Multidrug-resistant *Salmonella enterica* serotype Senftenberg
327 isolates producing CTX-M beta-lactamases from Constantine, Algeria. J Antimicrob
328 Chemother **56**:439-40

329 **Naas, T., Bentchouala, C., Cuzon, G., Yaou, S., Lezzar, A., Smati, F. &**
330 **Nordmann, P.** (2011). Outbreak of *Salmonella enterica* serotype Infantis producing
331 ArmA 16S RNA methylase and CTX-M-15 extended-spectrum β -lactamase in a
332 neonatology ward in Constantine, Algeria. Int J Antimicrob Agents **38**:135-9

333 **Ohmani, F., Khedid, K., Britel, S., Qasmaoui, A., Charof, R., Filali-Maltouf, A. &**
334 **El Aouad, R.** (2010). Antimicrobial resistance in *Salmonella enterica* serovar
335 Enteritidis in Morocco. J Infect Dev Ctries **4**:804-9.

336 **Paul, G.C., Gerbaud, G., Bure, A., Philippon, A. M., Pangon, B. & Courvalin, P.**
337 (1989). TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-
338 spectrum cephalosporins in a clinical isolate of *Escherichia coli*. Antimicrob. Agents
339 Chemother **33**:1958–1963.

340 **Ramdani-Bougoussa, N., Manageiro, V., Jones-Dias, D., Ferreira, E., Tazir, M. &**
341 **Canica, M.** (2011). Role of SHV β -lactamase variants in resistance of clinical
342 *Klebsiella pneumoniae* strains to β -lactams in an Algerian hospital. J Med Microbiol
343 **60**:983-7

344 **Rhimi-Mahjoubi, F., Bernier, M., Arlet, G., Jemaa, Z.B, Jouve, P., Hammami, A.**
345 **& Philippon, A. (2002).** Identification of plasmid-encoded cephalosporinase ACC-1
346 among various enterobacteria (*Klebsiella pneumoniae*, *Proteus mirabilis*,
347 *Salmonella*) isolated from a Tunisian hospital (Sfax 997-2000). *Pathol Biol (Paris)*
348 **50:7-11.**

349 **Tamang, M.D., Nam, H.M., Kim, T.S., Jang, G.C., Jung, S.C. & Lim, S.K. (2011).**
350 Emergence of extended-spectrum beta-lactamase (CTX-M-15 and CTX-M-14)-
351 producing nontyphoid *Salmonella* with reduced susceptibility to ciprofloxacin among
352 food animals and humans in Korea. *J Clin Microbiol* **49:2671-5**

353 **Touati, A., Benallaoua, S., Forte, D., Madoux, J., Brasme, L. & de Champs C.**
354 (2006). First report of CTX-M-15 and CTX-M-3 beta-lactamases among clinical
355 isolates of Enterobacteriaceae in Béjaia, Algeria. *Int J Antimicrob Agents* **27:397-**
356 **402.**

357 **Touati, A., Benallaoua, S., Gharout, A., Amar, A.A., Le Magrex Debar, E.,**
358 **Brasme, L., Madoux, J., De Champs, C. & Weill, F.X. (2008).** First report of CTX-
359 M-15 in *Salmonella enterica* serotype Kedougou recovered from an Algerian
360 hospital. *Pediatr Infect Dis J* **27:479-80.**

361 **Yates, C. & Amyes, S. (2005).** Extended-spectrum beta-lactamases in non-
362 typhoidal *Salmonella* spp. isolated in the UK are now a reality: why the late arrival?.
363 *J Antimicrob Chemother* **56: 262-4.**

364 **Table 1: Primers used in this study**

Target	Primer	Primer sequence	Reference
<i>bla</i> _{CTX-M}	CTX-M1-A2	5'-CTTCCAGAATAAGGAATC-3'	Dutour <i>et al.</i> , 2002
	628R	5'-CCTTTCATCCATGTCACCA-3'	Brasme <i>et al.</i> , 2007
	405F	5'-GTGGCGATGAATAAGCTGA-3'	Brasme <i>et al.</i> , 2007
	CTX-M1-B2	5'-CCGTTTCCGCTATTACAA-3'	Dutour <i>et al.</i> , 2002
<i>bla</i> _{TEM}	TEM-A	5'-TAAAATTCTTGAAGACG-3'	Chanal <i>et al.</i> , 2000
	TEM-B	5'-TTACCAATGCTTAATCA-3'	
<i>bla</i> _{SHV}	SHV-F	5'-ATGCGTTATATTCGCCTGTG-3'	Kojima <i>et al.</i> , 2005
	SHV-R	5'-TTAGCGTTGCCAGTGCTCGA-3'	

Table 2: Characteristics of Algerian clinical isolates of S. Brunei and S. Heidelberg resistant to broad-spectrum cephalosporins

Isolates	Isolation date	Ward	CXM	TIC	PIP	AMC	FEP	GPO	TCC	ATM	CTX	CAZ	TZP	IMP	FOX	Additional resistance	ESBL type
S. Brunei S10	23/04/1997	Neonatology	19 [R]	6 [R]	6 [R]	19 [I]	22 [I]	21 [I]	19 [R]	12 [R]	25 [I]	12 [R]	25 [S]	35 [S]	30 [S]	GEN, TOB, KAN, AMK	TEM-188
S. Brunei S12	20/09/1994	Neonatology	11 [R]	6 [R]	6 [R]	24 [S]	21 [I]	21 [I]	23 [I]	24 [I]	25 [I]	17 [R]	28 [S]	35 [S]	30 [S]	GEN, TOB, KAN	TEM-4
S. Brunei S15	19/03/2008	Neonatology	16 [R]	6 [R]	6 [R]	19 [I]	22 [I]	20 [I]	19 [R]	12 [R]	23 [I]	10 [R]	23 [S]	35 [S]	31 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S16	27/03/2008	Cradle	18 [R]	6 [R]	6 [R]	19 [I]	22 [I]	20 [I]	19 [R]	12 [R]	23 [I]	14 [R]	23 [S]	36 [S]	30 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S18	25/06/1998	Neonatology	17 [R]	6 [R]	6 [R]	19 [I]	22 [I]	21 [I]	20 [R]	12 [R]	23 [I]	10 [R]	23 [S]	35 [S]	29 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S20	19/03/2008	Neonatology	18 [R]	6 [R]	6 [R]	19 [I]	22 [I]	21 [I]	20 [R]	11 [R]	23 [I]	10 [R]	23 [S]	34 [S]	30 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S21	12/12/1995	Neonatology	18 [R]	6 [R]	6 [R]	19 [I]	21 [I]	20 [I]	19 [R]	12 [R]	23 [I]	10 [R]	23 [S]	35 [S]	30 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S22	26/07/1998	Neonatology	18 [R]	6 [R]	6 [R]	19 [I]	22 [I]	21 [I]	19 [R]	12 [R]	24 [I]	11 [R]	23 [S]	35 [S]	30 [S]	GEN, TOB, KAN, AMK	TEM-4
S. Brunei S23	12/02/1995	Neonatology	18 [R]	6 [R]	6 [R]	19 [I]	22 [I]	21 [I]	19 [R]	12 [R]	24 [I]	11 [R]	23 [S]	36 [S]	31 [S]	GEN, TOB, KAN, AMK, SUL	TEM-48
S. Brunei S9	22/03/1998	Neonatology	19 [R]	6 [R]	6 [R]	19 [I]	23 [I]	22 [I]	20 [R]	11 [R]	25 [I]	10 [R]	25 [S]	36 [S]	31 [S]	GEN, TOB, KAN	TEM-4
S. Heidelberg S1	26/10/2008	Cradle	6 [R]	6 [R]	6 [R]	24 [S]	11 [R]	9 [R]	22 [R]	12 [R]	11 [R]	14 [R]	26 [S]	36 [S]	31 [S]	GEN, TOB, NAL	CTX-M-15
S. Heidelberg S2	26/10/2008	Cradle	6 [R]	6 [R]	6 [R]	24 [S]	14 [R]	10 [R]	22 [R]	12 [R]	10 [R]	14 [R]	26 [S]	35 [S]	30 [S]	GEN, TOB, NAL	CTX-M-15
S. Heidelberg S3	16/10/2008	Cradle	6 [R]	6 [R]	6 [R]	24 [S]	14 [R]	10 [R]	22 [R]	12 [R]	10 [R]	13 [R]	28 [S]	35 [S]	30 [S]	GEN, TOB, NAL	CTX-M-15
S. Heidelberg S8	03/10/2008	Cradle	6 [R]	6 [R]	6 [R]	24 [S]	13 [R]	10 [R]	25 [R]	12 [R]	8 [R]	14 [R]	26 [S]	35 [S]	30 [S]	GEN, TOB, NAL	CTX-M-15

Legend:

CXM: cefuroxime, **TIC:** ticarcillin, **PIP:** piperacillin, **AMC:** amoxicillin-clavulanate, **FEP:** cefepime, **CPO:** cefpodoxime, **CTX:** cefotaxim, **CAZ:** ceftazidime, **TZP:** piperacillin-tazobactam, **IMP:** imipenem, **FOX:** ceftiofur, **GEN:** gentamicin, **TOB:** tobramycin, **Kan:** kanamycin, **AMK:** amikacin, **SUL:** sulfonamide, **[R]** : Resistant, **[S]**: Susceptible, **[I]**: Intermediary.

Table 3: MICs of β -lactams for *S. Brunei* and *S. Heidelberg* producing ESBL

Code	ESBL	CTX	AMX	CFT	CAZ
S. Heidelberg S1	CTX-M-15	>32	>256	>32	48
S. Heidelberg S2	CTX-M-15	>32	>256	>32	48
S. Heidelberg S3	CTX-M-15	>32	>256	>32	48
S. Heidelberg S8	CTX-M-15	>32	>256	>32	48
S. Brunei S10	TEM-188	16	>256	12	32
S. Brunei S12	TEM-4	16	>256	6	64
S. Brunei S22	TEM-4	16	>256	6	64
S. Brunei S9	TEM-4	16	>256	6	64
S. Brunei S15	TEM-48	16	>256	6	64
S. Brunei S16	TEM-48	16	>256	6	64
S. Brunei S18	TEM-48	16	>256	6	64
S. Brunei S20	TEM-48	16	>256	6	64
S. Brunei S21	TEM-48	16	>256	6	64
S. Brunei S23	TEM-48	16	>256	6	64

Legend: AMX: amoxicillin, CTX: cefotaxime, CAZ: ceftazidime, CFT: ceftriaxone